IndustryCompany release

Cryoport lifts 2026 revenue outlook to $197M-$199M after 14% third-quarter growth

🇺🇸 Cryoport, Inc. (CYRX) · Thu 05 Nov 2026

The cell and gene therapy logistics provider reported third-quarter revenue of $50.2 million, a net loss of $10.9 million and adjusted EBITDA of $1.1 million.

Cryoport, a US provider of temperature-controlled supply chain services for cell and gene therapies, reported third-quarter 2026 results on 5 November. Revenue rose 14% to $50.2 million.

The company linked the growth to a 20% increase in revenue from commercial cell and gene therapy clients. It posted a net loss of $10.9 million for the quarter and adjusted EBITDA of $1.1 million.

Cryoport said it now supports 23 commercial therapies and a record 788 clinical trials. Based on the quarter, it raised its full-year 2026 revenue guidance to a range of $197 million to $199 million.

The summary provided does not include further detail on regional performance, the previous guidance range or individual client programmes.

What it means for your team

  • Growth in commercial-stage cell and gene therapy revenue suggests more products are moving from trials into routine distribution, increasing demand for validated cold-chain logistics.
  • A record 788 supported clinical trials points to a sustained pipeline of advanced therapies that will need controlled, traceable shipping.
  • Quality and supply-chain teams may wish to check that logistics partners have capacity for commercial-scale volumes alongside clinical shipments.

Company's press release (SEC filing): Cryoport, Inc. ↗

Article written by VigiEye from the official source (Cryoport, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →